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Mast cell activation syndrome (MCAS) is a relatively recently recognized cause of chronic multisystem polymorbidity
of a generally inflammatory theme. Patients with MCAS often report migratory soft tissue and/or bone pain which
frequently responds poorly to typical (narcotic and non-narcotic) analgesics as well as atypical analgesics such as
antidepressants and anticonvulsants. Hydroxyurea (HU) is an oral ribonucleotide reductase inhibitor commonly used
in the treatment of chronic myeloproliferative neoplasms and sickle cell anemia. HU has been used to treat
systemic mastocytosis, sometimes effecting improvement in MC activation symptoms but not tumor burden,
suggesting potential utility of the drug in MCAS, too. Reported here are five cases of successful use of relatively
low-dose HU in MCAS to reduce symptoms including previously refractory soft tissue and/or bone pain. HU may be
useful in treating mediator symptoms in MCAS, but further study is needed to define optimal dosing strategies and
patient subpopulations most likely to benefit.
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Mast cell activation syndrome (MCAS, a more prevalent
but only recently recognized cousin of the rare, prolifer-
ative mast cell (MC) disease mastocytosis) typically
causes chronic multisystem polymorbidity of a generally
inflammatory theme [1]. The MC activation seen in
either mastocytosis or relatively non-proliferative MCAS
often results in migratory soft tissue and/or bone pain
which frequently responds poorly to typical (narcotic
and non-narcotic) analgesics as well as atypical analge-
sics such as antidepressants and anticonvulsants.
Hydroxyurea (HU) is an oral ribonucleotide reductase
inhibitor with antimetabolic and antineoplastic proper-
ties [2]. First used clinically in the 1960s for chronic my-
eloproliferative neoplasms (MPNs) [3], HU was shown
to raise fetal hemoglobin (HbF, α2γ2) levels in sickle cell
disease (SCD) in 1985 [4], and it is now apparent that the
requisite increase in γ-globin expression occurs via mul-
tiple mechanisms including, at a minimum, erythropoietic
cytotoxicity leading to “stress erythropoiesis” with increa-
sed HbF levels, nitric oxide production, and the soluble
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stated.pathway [2]. Continued clinical research culminated in a
Phase 3 double-blind randomized controlled trial pub-
lished in 1995 [5] clearly establishing the utility of the
drug in reducing the severity of sickle cell anemia (SCA).
It also inhibits replication of human immunodeficiency
virus-1 (HIV-1) [6] and has been used in cyanotic con-
genital heart disease [7]. The efficacy of HU for these
varied clinical conditions appears to be due, at a mini-
mum, to its potent inhibition of ribonucleotide reductase,
a ubiquitous intracellular enzyme that converts ribonu-
cleotides to deoxyribonucleotides, which are required for
DNA synthesis and repair [8].
Although concerns have been expressed for potential
tumorigenicity (especially leukemogenicity) of HU in the
treatment of MPNs, analysis of these concerns has been
confounded by the inherent leukemogenicity of these
diseases. More recent retrospective and prospective ana-
lyses of long-term hydroxyurea use in the MPNs have
been more reassuring regarding the drug’s previously
alleged potential for fomenting malignant transformation
[9-11]. In the non-malignant setting of SCD, too, data
on the safety of long-term HU use have been similarly
reassuring [12-16].
HU has been used in the treatment of mastocytosis,
too, and has been associated with reductions in MC loads is an Open Access article distributed under the terms of the Creative
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without clear reduction in MC load (e.g., malaise and
pruritus [18]; progressive decrease in clinical symptoms
and the need for intensive antimediator therapy [19];
weight loss, severe night sweats, abdominal pain, and
pruritus [20]; facial flushing and bone pain [21]; and
pruritus, flushing, ascites, and hepatosplenomegaly [22]).
These reports suggest HU might be able to modulate
MC mediator expression in some patients independent
of its anti-proliferative effects.
Reported here are five cases of successful use of HU in
MCAS to reduce symptoms. Each patient was diagnosed
with MCAS after prior extensive evaluations failed to
find any evident disease better explaining the full range
of findings in the case and upon finding symptoms,
physical exam findings, and laboratory evidence consist-
ent with chronic aberrant MC mediator expression [1].
All five patients responded to assorted sets of MCAS-
directed therapies. Of note, in all five patients modest
doses of HU promptly, markedly reduced their diffuse
aching, though cytopenias required stopping the drug in
one patient, and reactions to one formulation of the
drug in another three patients required trials of an
alternative formulation.
Case 1
A 55 year old white male airline pilot was referred in
June 2009 for further evaluation of non-palpable spleno-
megaly discovered in the evaluation of chronic, waxing/
waning nausea and left-sided abdominal pain, non-
bloody emesis, early satiety, and mild weight loss that
had emerged in the wake of an episode of alleged food
poisoning in 2005. His flight privileges were revoked
upon discovery of the splenomegaly, and he took a part-
time retail sales position. Past history was notable for
persistent problems with episodic diffusely migratory
musculoskeletal pain complaints since unexplained left
shoulder bursitis at age 9; repeated evaluations of these
episodes were non-diagnostic. In addition to his gastro-
intestinal/abdominal symptoms, review of systems also
revealed a sense of frequent variation in body tempera-
ture, sometimes even with mild rigors; near daily night
sweats; episodic diffusely migratory edema; pruritic
erythematous rash about the inferior neck; occasional
acute spells of severe diffuse pruritus; waxing/waning
dysgeusia and dysosmia; chronic tinnitus; chronic
fatigue to the point of inability to get out of bed on
some mornings; unpredictable/unprovoked acute-onset
episodes every few days to every few weeks of light-
headedness and flushing; frequent palpitations; chro-
nically irritated eyes; marked gastroesophageal reflux
(intolerant of esomeprazole but improved with rani-
tidine); chronic back pain and diffusely migratory
polyarthritis; alternating diarrhea and constipation;poor healing; and occasional diffusely migratory tin-
gling/numbness paresthesias.
Examination was notable only for tenderness to palpa-
tion across the upper abdomen (worst in the epigas-
trium) and the above-noted neck rash but without
pruritic behaviors. Small cherry angiomata were sparsely
scattered about his skin. Moderate dermatographism
was noted.
Serum tryptase was normal. Upon finding an elevated
urinary prostaglandin D2 (PGD2) level during an “attack”
plus increased (but non-aggregated, non-spindled) MCs
by bright CD117 immunohistochemical staining in mul-
tiple gastrointestinal (GI) tract mucosal biopsies, MCAS
was diagnosed. He gained incremental improvement
with loratadine and famotidine and then aspirin, then
quickly proved intolerant of serial trials of clonazepam,
lorazepam, doxepin, quercetin, ketotifen, cromolyn,
montelukast, and low-dose imatinib (200 mg daily), and
then gained further improvement with low-dose dasa-
tinib at 40 mg daily. Waxing/waning, diffusely migra-
tory soft tissue and bone pain (typically 7/10 or worse)
persisted without improvement, often was disabling,
and proved refractory to a wide variety of analgesics
prescribed by his local physicians. Hydrea-brand HU
was begun in December 2011, initially at 500 mg daily,
escalating weekly.
He returned in February 2012, having reached the
prescribed target dose of 1500 mg daily. He reported the
drug had initially worsened his nausea, abdominal dis-
comfort, diarrhea, headache, and malaise, but after a
week these symptoms completely resolved and his dif-
fuse soft tissue pain completely resolved, too. He was
able to stop aspirin and other occasional use of non-
steroidal anti-inflammatory drugs (NSAIDs).
Two weeks later he reported new dyspnea. Thorough
cardiopulmonary evaluation was unrevealing. Dasatinib
was stopped.
In March 2012 soft tissue pain mildly relapsed, and
HU had to be reduced to 500 mg daily due to excessive
cytopenias. Fatigue, bone pain, headaches, palpitations,
and diarrhea quickly relapsed, but there was insufficient
improvement in cytopenias and the drug was fully
stopped in April 2012. Dasatinib was restarted at 40 mg
daily. Two weeks later he reported moderate improve-
ment in many symptoms, but soft-tissue and bone pain
continued. By August 2012 he was having so much
trouble attending to his work due to his pain that he
was considering applying for disability. Droxia-brand
HU was tried at 200 mg daily, but it seemed to persist-
ently exacerbate his left upper quadrant abdominal pain
and was stopped after a month.
A trial of lorazepam compounded with baby rice cereal
proved helpful for his soft tissue and bone pain. As of
August 2013 he was well most of the time and controlling
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He was attending well to his part-time job and was
reapplying for flight privileges.
Case 2
A 29 year old disabled male manufacturing supervisor
presented in August 2010 for further evaluation of a
wide spectrum of chronic idiopathic problems domi-
nated by diffusely migratory soft-tissue pain. Other than
neonatal pulmonic valve repair and a number of acci-
dental traumas in childhood, his early medical history
was unrevealing, but at age 14 migraine headaches with
attendant cognitive dysfunction (“brain fog”) suddenly
developed and had persisted, waxing and waning, ever
since. The headaches had often been attributed to
chronic sinusitis, but the many sinusitis treatments he
had tried had been uniformly unhelpful. By age 17 he
was sleeping through many classes because classroom
lights sometimes triggered headache flares. He suffered
four more major accidental traumas at ages 17–18, once
requiring resuscitation. He worked for a decade after
finishing high school but had been unemployed since
age 28 due to chronic right shoulder and back pain aris-
ing from a work-related accident. He also noted marked
bilateral lower extremity pain had emerged in the
months after the accident and was also attributed to this
accident, although the only finding on a lumbosacral
magnetic resonance imaging (MRI) scan was old right
S1 pedicle trauma. His chief complaint was diffusely
migratory pain, worst in the legs as a crampy, achy
throbbing. Lorazepam and clonazepam tended to help
his pain noticeably more than traditional analgesics, but
his physicians were reluctant to regularly prescribe
benzodiazepines.
On review of system he also noted severe gastroesoph-
ageal reflux for the prior decade, with frequent non-
bloody post-prandial emesis. Esomeprazole helped only
modestly. Spicy foods reliably triggered the reflux. Bidir-
ectional endoscopy in 2004 to investigate an unrepeated
episode of rectal bleeding was non-diagnostic. Episodic
migratory swelling of his bilateral feet, ankles, and hands
was also noted. Other problems included many years of
intermittent subjective and objective idiopathic fevers,
frequent night sweats, occasional chills, episodic dif-
fusely migratory pruritus, eye and throat irritation, intra-
nasal sores, deteriorating dentition, proximal dysphagia,
waxing/waning dyspnea, palpitations, panic attacks,
presyncope, syncope, diarrhea alternating with consti-
pation, tinnitus, insomnia, poor healing, and diffusely
migratory tingling/numbness paresthesias. Extensive
evaluations by a variety of specialists had been unreveal-
ing. He denied medication allergies. Past medical history
included hypertension. He had not used illegal sub-
stances since adolescence.Exam was notable for fatigue, cane-assisted ambu-
lation, and obvious whole body discomfort with any
motion. His skin was diffusely freckled. There were small
lipomas scattered about his body which he noted had
been progressing in number for several years. There was
diffuse mild abdominal tenderness to deep palpation and
4/5 strength in all distal extremities; reflexes were intact.
Moderate dermatographism was noted.
He appeared diffusely inflamed, but no specific inflam-
matory ailment had been identified in years of evaluation.
Normal bone densitometry was noted. Porphyrin screen-
ing was negative. Serum tryptase was normal. In addition
to mild relative eosinophilia, elevations in plasma PGD2
and histamine were found. MCAS was diagnosed. Lo-
ratadine and famotidine immediately provided major
improvements in reflux, dyspnea, fevers, pruritus, and eye
and nasal irritation. A one-month trial of celecoxib was
moderately helpful for pain, but access to the drug could
not be maintained. Serial trials of montelukast and azathi-
oprine provided no additional benefit; trials of doxepin
and low-dose imatinib quickly proved intolerable. Loraze-
pam proved helpful to varying degrees for sleep, malaise,
anxiety and panic attacks, fevers, sweats, and palpitations
but only mildly helpful for his diffuse pain.
In August 2012 HU was begun at 500 mg daily. For
his first four-week supply, his pharmacist provided him
two-week supplies of formulations from PAR and Barr.
In the first two weeks using the Barr formulation, his leg
pain was significantly improved, but three days after
switching to the PAR formulation, all of his symptoms
markedly worsened. Emergency room evaluation was
unrevealing. He stopped HU and soon returned to his
prior baseline. HU was then tried again with Droxia
200 mg capsules, which immediately reduced his diffuse
pain from a persistent 10/10 at baseline to a sustained 6/10.
No further improvement was seen at 200 mg twice daily
dosing, but at 400 mg twice daily dosing, pain was
substantially further reduced to 3/10. There was no
hematologic toxicity. As of July 2013 he reported feeling
comfortable and did not need further adjustments to his
regimen.
Case 3
In February 2011 a 55 year old disabled male business-
man was referred for further evaluation of anemia and
thrombocytopenia. He reported a lifelong history of
multisystem polymorbidity of a generally inflammatory
theme, including frequent upper and lower respiratory
tract infections and “lots of diarrhea” ever since infancy.
His parents were often upset with him about his illnesses
and often suspected they were factitious. He also had
been afflicted since his 20s by chronic diffusely migra-
tory bone and joint and back pains. Chronic headaches
and fatigue emerged in his 30s, and by his mid-40s
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refractory to aggressive medical and surgical therapies.
On review of systems he endorsed fevers, chills, soaking
sweats, diffusely migratory pruritus, spontaneous bruis-
ing, irritation of his eyes/nose/mouth/throat, hoarseness,
cough occasionally productive of clear or colored sputum,
dyspnea, chest pain requiring frequent emergency room
evaluations which were always unrevealing, palpitations,
proximal dysphagia, nausea, bloody and non-bloody
vomiting, alternating diarrhea and constipation, urinary
hesitancy and frequency, dysuria, diffusely migratory
macular erythematous rash, diffusely migratory tingling/
numbness paresthesias, diffusely migratory edema, poor
healing, cognitive dysfunction, depression, presyncope,
syncope, and panic attacks. In spite of all of these prob-
lems he had run a business for many years before progres-
sive ailment disabled him at age 50. Past medical history
included hypertension, hyperlipidemia, and pulmonary
sarcoidosis in ‵87 treated with a right upper lobectomy; he
had been dealing with a “low-grade” Mycobacterium
avium intracellulare infection ever since and had been
alternately told that possibly this or chronic aspiration
might be causing many of his problems. The family
history was rife was assorted cancers. His only known
medication allergy was a penicillin-induced rash.
Exam was notable for a chronically ill, mildly diapho-
retic general appearance, diffusely achy movement, and
mild tenderness to palpation across the upper abdomen.
Strong dermatographism was noted. He had had a mild
normocytic anemia and mild thrombocytopenia for only
the prior year; leukocyte count was normal, but eosino-
phils were 16%. Very extensive prior evaluations by mul-
tiple specialists had been unrevealing. Immunoglobulin
G and M levels were normal, but IgA was found severely
deficient. Sputum stains and cultures were negative,
including testing for acid-fast bacilli. Serum tryptase was
normal. Elevations in serum and urinary PGD2 were
found. MCAS and IgA deficiency (more likely secondary
to MCAS in view of his prior tolerance of red blood cell
transfusions) were diagnosed.
Histamine H1 and H2 blockers were unhelpful. A trial
of anti-inflammatories was desired, but aspirin and other
traditional NSAIDs were felt to be contraindicated.
Celecoxib lessened his fatigue, flushing, bruising, irri-
tability, and cough. Low-dose cromolyn significantly
reduced his abdominal discomfort and GI symptoms.
Doxepin was unhelpful. Ketotifen further improved his
energy. Low-dose lorazepam, too, further helped his
malaise and GI symptoms, but diffusely migratory soft-
tissue, bone, and joint pain remained a chief complaint.
In February 2013 Hydrea-brand HU was begun at
500 mg daily. In March 2013 he reported his bone pain
was reduced; HU was increased to 1000 mg daily. In
April 2013 he reported his bone pain had becometolerable. In May 2013 he stopped HU due to concerns
it might interfere with healing from Mohs surgery, and
his bone pain fully relapsed within a few days. He was
unsure whether he was fully tolerating Hydrea. Droxia-
brand HU was begun at 200 mg daily. His constant 8/10
bone pain immediately decreased to 2/10, and his cough
and sputum production almost completely resolved, too.
There was no hematologic toxicity. His muscle pain,
though, was unimproved, and he was planning to try
increasing his Droxia.
Case 4
In January 2012 a 30 year old female laboratory tech-
nologist was referred for further evaluation of suspected
mast cell disease. She had been healthy until an emer-
gency Cesarean section was required at age 19 due to
infection, after which she developed generalized weak-
ness and bilateral lower extremity bone and joint pains
which never resolved. At age 24, shortly after her father
died, significant alopecia and chronic fatigue emerged,
and the chronic aching extended to involve her hands,
too. In 2008 her fatigue was assumed to be due to
obstructive sleep apnea for which she underwent ton-
sillectomy and septoplasty, the only apparent result of
which was worsening of fatigue and joint pains. Multiple
rheumatologic and neurologic evaluations were negative
except for tentative conclusions (based on modest eleva-
tions in ANA) of lupus for which trials of Plaquenil and
methotrexate never yielded any discernible improve-
ment. “Cigarette-burn-like” rashes sometimes like hives
and often leaving scars, together with diffusely migratory
pruritus, emerged at age 29. Joint pains came to involve
her elbows, largely incapacitating her use of her arms.
Frequent nausea and diarrhea alternating with cons-
tipation emerged, too, but extensive gastroenterologic
evaluation was negative. On review of systems, she also
endorsed waxing/waning issues subjective fevers, chills,
soaking sweats, flushing, diffusely migratory marked ach-
ing, dysmenorrhea, headaches, irritated eyes, frequent cor-
yza, irritated mouth, mild dyspnea, proximal dysphagia,
palpitations, refractory gastroesophageal reflux, diffusely
migratory edema, diffusely migratory tingling/numbness
paresthesias, spontaneous bruising, episodic cognitive
dysfunction, and daily presyncope. There were multiple
cancers in the family history. Her only known allergy was
a sulfa-induced rash.
Exam found a tired, overweight, achy woman with a
sparse scattering of small macular dark or lightly ery-
thematous lesions, slight tenderness at all nodal stations,
and an abdomen notable for diffuse mild tenderness and
diaphoresis, and trace distal edema. Moderately bright
dermatographism was noted. Serial complete blood
counts were notable only for a stable borderline micro-
cytosis, chronic mild leukocytosis (with frequent minimal
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was chronically minimally elevated. Anti-nuclear anti-
bodies were mildly elevated, C-reactive proteins were
persistently significantly elevated, and erythrocyte sedi-
mentation rates were normal. Extensive thyroid testing
was normal.
Serum tryptase was normal, but plasma histamine and
urinary PGD2 were found elevated (this last in spite of
ongoing, if ineffective, use of ibuprofen). MCAS was
diagnosed. Loratadine and famotidine immediately
resolved her rash. Aspirin, lorazepam, doxepin, quer-
cetin, and cromolyn were unhelpful. Montelukast 10 mg
twice daily (but not once daily) improved her fatigue and
emotional lability.
In April 2013, in view of her diffusely migratory pain
being her chief complaint, Hydrea-brand HU was initi-
ated at 500 mg daily. This immediately began helping
her pain and nausea. She previously had needed to often
recline and take weight off her legs due to throbbing
pain throughout her legs (typically 8/10 or worse), but
HU allowed her to stay upright throughout the day.
These improvements were amplified upon increasing the
dose to 1000 mg daily and were sustained as of July
2013 (pain score 3/10). There was no hematologic
toxicity.
Case 5
In October 2010 a 62 year old retired law enforcement
officer was referred for further evaluation of heterozy-
gous alpha-1-antitrypsin deficiency discovered while
being evaluated for mysterious chronic debilitating illness.
Crohn’s disease had been diagnosed by colonoscopic
biopsy in 2003. Mesalamine was unhelpful for his diarrhea.
Repeat endoscopy in 2009 led to a change in diagnosis to
lymphocytic colitis. Budesonide resolved his diarrhea. Sev-
eral months later (one month after a trip), a left lower
extremity deep venous thrombosis and bilateral pulmon-
ary emboli developed. Chronic anticoagulation was begun.
He began rapidly losing weight. Budesonide was stopped.
Diarrhea did not immediately relapse. Past history inclu-
ded chronic back and bilateral leg pain since a work-
related fall in 1967. On review of systems, he endorsed
chronic fatigue, anhedonia, depression, lethargy, feeling
cold all the time since starting warfarin, heat intolerance,
diffuse aching since 2009, tinnitus, constant coryza, throat
irritation, dry cough, constant hunger, constipation (pos-
sibly from chronic oxycodone use), urinary frequency, fre-
quent confusion, easy irritability, and frequent presyncope.
He was an active smoker with a 100-pack-year cigarette
history.
Exam found a thinning, worried man with livedo
reticularis across the low back and mild dermato-
graphism. Extensive prior laboratory testing was notable
only for stable mild elevations in hepatic transaminases.The serum ferritin was twice the upper limit of normal.
Liver biopsy showed him to be heterozygous for alpha-
1-antitrypsin deficiency but did not show alpha-1-
antitrypsin globules.
Serum tryptase was normal. Plasma PGD2 was double
the upper limit of normal. Factor VIII was markedly
elevated at 400% (normal 50-150%). CD117 immunohis-
tochemical staining of endoscopic biopsies from 2009
showed significantly increased (though non-aggregated,
non-spindled) mast cells. MCAS was felt likely, possibly
with a comorbid Factor VIII-overexpressing hypercoa-
gulable state, though given that Factor VIII is a known
MC mediator, his hypercoagulable state could have been
secondary to his MCAS.
He started loratadine and famotidine and soon noted
mild to moderate improvement in almost all symptoms,
but diffusely migratory aching was unimproved.
Montelukast was unhelpful. Aspirin further helped many
of his symptoms but, again, not the aching. Low-dose
lorazepam mildly reduced his pain. Doxepin was unhelp-
ful. Cromolyn essentially resolved his GI symptoms.
Low-dose imatinib (200 mg daily) reduced his fatigue
and cognitive dysfunction and finally provided him
“more good days than bad,” but diffuse aching was un-
improved, typically 8/10 or worse.
In February 2013 Hydrea-brand HU was initiated at
500 mg daily but immediately proved intolerable (nausea,
vomiting, chills). In April 2013 Droxia-brand HU was
initiated at 200 mg daily. In June 2013 he reported signifi-
cant reduction in not only fatigue but also diffuse aching
(3/10) and presyncope. There was no hematologic toxicity.
As of July 2013 he was planning to try escalating the
Droxia dose.
Discussion
Of hematopoietic origin, mast cells (MCs) are found in
all human tissues, especially at the environmental inter-
faces and perivascular/perineural sites [23]. They serve
largely as sentinels of environmental change and bodily
insults and respond by releasing large and variable
assortments of molecular mediators which directly and
indirectly influence behavior in other (local and distant)
cells and tissues to respond to changes/insults so as to
maintain, or restore, homeostasis. The transmembrane
tyrosine kinase receptor KIT is the dominant MC regu-
latory element, shown to be critical for key MC func-
tions including survival, differentiation, chemotaxis, and
activation [24].
Traditionally, MC disease has been thought to be
principally a matter of neoplastic burdens of MCs, with
symptoms resulting principally from an accompanying
inappropriate release of mediators from these excessive
numbers of MCs. Nearly a quarter century ago, though,
the notion was first advanced that there might be forms
Table 1 Treatments used in mast cell activation disease
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Immunomodulation Allergy desensitization therapy
Allogeneic stem cell transplantation
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lease with little to no accompanying proliferation of
MCs [25]. This theory appeared validated when the first
recognized cases of what is now called MC activation
syndrome (MCAS) were published in 2007 [26-28]. Dif-
ferent patterns of aberrant expression of the large MC
mediator repertoire in different MCAS patients make
for markedly heterogeneous – and thus diagnostically
challenging – presentations [1]. The cause of such het-
erogeneity is not yet clear. Provocatively, though, Mold-
erings et al. have repeatedly found a wide array of
(presumably mostly constitutively activating) mutations
scattered across all domains of KIT in small cohorts of
MCAS patients, with most of their studied patients bear-
ing multiple mutations in no yet-apparent recurring pat-
terns [28,29]. (Interestingly, the KITD816V mutation so
common in mastocytosis seems rare in MCAS.) Though
these findings have not yet been independently con-
firmed, it is noteworthy that similar mutational com-
plexity (in KIT and other cellular controllers) has been
found, too, across the spectrum of chronic myelo-
proliferative neoplasms (MPNs) within which the MC
disorders reside [30], and in advanced mastocytosis
itself [31].
Given these new biologic and clinical insights, pro-
posals have emerged to consider all MC diseases under
the umbrella term of MC activation disease (MCAD)
[32]. It also has been proposed that the assorted sys-
temic MCAD variants and clinical phenotypes represent
not distinct disease entities but instead varying presenta-
tions of a common generic root process of mast cell dys-
function [33]. Mastocytosis may be merely the tip of the
proverbial MCAD iceberg, fairly readily recognizable (in
spite of its rarity) because of its distinctive clinicopatho-
logic presentation, while the bulk of the iceberg – hidden
below the waterline of easy clinical recognizability – may
be a far larger, and far more heterogeneous, collection of
variants of MCAS, some of which are already discretely
recognized (e.g., idiopathic anaphylaxis [27], cryopyrin-
associated periodic syndrome [34]), but most not.
With no predictors of therapeutic response yet identi-
fied, MCAD’s heterogeneity poses not only diagnostic
but also therapeutic challenges (Table 1). The cases in
the present series extend earlier observations that HU
appears able to modulate MC mediator expression in
MCAD, including MCAS, and may be particularly useful
to treat pain in patients refractory to, or intolerant of,
other typical and atypical analgesics. Although all of the
patients reported here were already on some anti-
mediator therapy at the time HU was begun, the fact
that initiation of HU was the only medication change
preceding the observed further symptomatic improve-
ments strongly suggests HU was solely responsible for
these improvements.Three of the patients in this series quickly showed
intolerance of a commonly used formulation of HU but
then tolerated, and responded well to, an alternative
formulation, possibly due to the propensity of MCAD
patients to manifest odd and prolific medication sensiti-
vities which may result from MC reactions to either “ac-
tive” or “inactive” ingredients. It may be worthwhile
when designing therapeutic trials for the MCAD popu-
lation to allow for switching to alternative medication
formulations when intolerance of a given formulation
quickly becomes apparent. Such a strategy may reduce
the chance of underestimating tolerability and efficacy.
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may gain further significance in light of the recent dis-
covery by Vincent et al. that in a murine model of sickle
cell anemia (SCA), MC activation was found to underlie
sickle pathophysiology leading to inflammation, vascular
dysfunction, pain, and requirement for high doses of
morphine [35]. HU is used as a disease-modifying agent
in sickle cell disease (SCD) and is the only approved
such agent, though red blood cell transfusions, too, can
greatly decrease disease severity and hematopoietic stem
cell transplantation can cure SCD [36]. Despite use of
HU in this fashion for more than 25 years, the full set of
mechanisms by which it reduces SCD severity remains
unclear. The efficacy of HU in the treatment of SCD is
generally attributed to its ability to increase HbF, but in
a recent systematic review of the efficacy of HU in SCD,
the sole identified randomized controlled trial reported
the mean increase in HbF from two years of HU use was
only 3.2% [37], while other salutary benefits of HU in
SCD not clearly related to increases in HbF have been
observed, too, including lowering of circulating leuko-
cyte counts and local release of nitric oxide [2]. It is
unclear whether HU’s established activity as a ribonucle-
otide reductase inhibitor is the sole molecular mecha-
nism of action through which all of these benefits arise.
Thus, given the recent data from Vincent et al., the
overlap in the patterns of pain in both SCD and MCAS,
estimates of significant (14-17%) prevalence of MCAS in
the general population [33,38], and the observations
from the present case series of the utility of HU in the
management of otherwise refractory pain in some
MCAS patients, at least two additional questions are
raised: (1) might unrecognized MCAS account for some
of the comorbidities which have long been seen in some
SCD patients, and attributed to their SCD, but for which
it has been difficult identifying specific biologic pathways
supporting such attribution, and (2) might treatment of
unrecognized MCAS be another mechanism by which
HU helps in SCD?
Conclusions
MCAS should be considered in the differential diagnosis
of diffusely migratory soft tissue, bone, and/or joint
pain. HU appears useful in treating an assortment of
mediator-driven symptoms in some patients with
MCAS. In particular, HU may be useful in addressing
otherwise refractory soft tissue and/or bone pain in
MCAS, but further study is needed to define HU’s
mechanisms of action in MCAD/MCAS, optimal dosing
strategies, and which patient subpopulations are most
likely to benefit. Further study may also be warranted to
characterize the prevalence and behavior of MCAS in
SCD patients, particularly those with comorbidities not
easily attributable to erythrocyte sickling.Consent
Written informed consent was obtained from each
patient for inclusion in publication of this case series.
Copies of the written consents are available for review
by the Editor-in-Chief of this journal.
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